31
Participants
Start Date
November 30, 2014
Primary Completion Date
April 20, 2020
Study Completion Date
April 20, 2020
Bortezomib
"1.3 mg/m2 subcutaneously\* days 1, 4, 8 and 11 of each cycle. Number of cycles: Four 21 day cycles (participants not suitable for ASCT (autologous stem cell transplant) will continue up to 6 cycles on the treatment regimen to which they were randomised).~\*intravenous infusion available in case of patient intolerance to subcutaneous bortezomib"
Thalidomide
100 mg daily orally, preferably at night, days 1-21 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
Bendamustine
60 mg/m2 i.v. days 1 and 8 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
Dexamethasone
40mg orally days 1-2, 4-5, 8-9 and 11-12 of each cycle
Basingstoke & North Hampshire Hospital, Basingstoke
Heartlands Hospitals, Birmingham
St Helier Hospital, Epsom
Royal Liverpool Hospital, Liverpool
Kings College Hospital, London
Queen Alexandra Hospital, Portsmouth
Great Western Hospital, Swindon
Kent & Canterbury Hospital, Canterbury
Churchill Hospital, Oxford
Janssen-Cilag Ltd.
INDUSTRY
Bloodwise
OTHER
University of Warwick
OTHER
University of Birmingham
OTHER
Oxford University Hospitals NHS Trust
OTHER